COVID-19 associated Mucormycosis among ICU patients: risk factors, control, and challenges

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Mycology

Background:

• The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic presents significant global challenges due to viral spread and emerging variants.
• Critically ill COVID-19 patients face increased opportunistic infections due to factors like disrupted infection control, steroid/antibiotic use, hospital crowding, and oxygen mask reuse.
• Patients with comorbidities (diabetes, malignancy, hemodialysis) and those on deferoxamine are particularly susceptible to opportunistic pathogens, including bacteria and fungi.

Purpose of the Study:

• To review the risk factors contributing to opportunistic infections in COVID-19 patients.
• To highlight the challenges posed by co-infections, especially fungal infections like mucormycosis, during the pandemic.
• To discuss current and potential control measures against opportunistic pathogens in the context of COVID-19.

Main Methods:

• This is a review article.
• Literature search on opportunistic infections in COVID-19 patients.
• Analysis of risk factors, challenges, and control strategies.

Main Results:

• COVID-19 management practices and patient comorbidities significantly increase the risk of opportunistic infections.
• Mucormycosis has emerged as a notable opportunistic fungal infection associated with COVID-19 globally.
• Effective management requires addressing both viral load and secondary pathogen burden.

Conclusions:

• Vulnerable patient populations require vigilant monitoring for opportunistic infections during SARS-CoV-2 infection.
• Addressing risk factors and implementing targeted control measures are crucial for managing co-infections.
• Further research into preventative and therapeutic strategies for opportunistic infections in COVID-19 is warranted.